Research and analysis

NHS Cervical Screening Programme Audit of invasive cervical cancer: Appendix B: Data Tables

Published 30 November 2023

Applies to England

© Crown copyright 2023

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/cervical-screening-invasive-cervical-cancer-audit-2016-to-2019/nhs-cervical-screening-programme-audit-of-invasive-cervical-cancer-appendix-b-data-tables

1. NHS Cervical Screening Programme Audit of invasive cervical cancer: Appendix B: Data Tables

August 2023

1.1 Appendix B: Data tables

Table 1. Number and proportion of cases of invasive cervical cancer by audit year and age at diagnosis

Audit year*
Age Group 2007 to 2008 2008 to 2009 2009 to 2010 2010 to 2011 2011 to 2012 2012 to 2013 2013 to 2014 2014 to 2015 2015 to 2016 2016 to 2017 2017 to 2018 2018 to 2019 Total
<25£ 44 29 33 29 23 35 27 21 19 8 10 7 285  
25-29 249 329 408 343 387 400 424 422 454 351 323 287 4377  
30-39 629 664 747 564 609 593 582 586 597 592 600 599 7362  
40-49 437 471 529 459 552 455 449 463 469 469 474 439 5666  
50-64 370 383 401 415 412 427 366 406 403 450 435 408 4876  
65+ 404 414 402 365 377 392 362 343 325 312 290 315 4301  
Total 2,133 2,290 2,520 2,175 2,360 2,302 2,210 2,241 2,267 2,182 2,132 2,055 26,867  

*Audit year between 1 April and 31 March

£Note that women diagnosed aged 24.5 to 25 are included in the age group 25 to 29.

Table 2. Number and proportion of invasive cervical cancer cases by audit year and 5 year age group

Audit Year1 <20* 20 to 24£ 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 55 55 to 59 60 to 64 65 to 69 70 to 74 75 to 79 80+ Total
2007 to 2008 0 44 249 308 321 251 186 132 122 116 91 87 83 143 2133
2008 to 2009 1 28 329 311 353 290 181 133 136 114 94 82 86 152 2290
2009 to 2010 0 33 408 379 368 310 219 141 134 126 94 90 76 142 2,520
2010 to 2011 0 29 343 274 290 259 200 155 128 132 93 71 72 129 2,175
2011 to 2012 1 22 387 302 307 322 230 156 134 122 88 73 88 128 2,360
2012 to 2013 1 34 400 329 264 259 196 158 157 112 112 83 85 112 2,302
2013 to 2014 1 26 424 307 275 243 206 151 122 93 107 66 78 111 2,210
2014 to 2015 1 20 422 304 282 258 205 165 132 109 91 62 84 106 2,241
2015 to 2016 0 19 454 309 288 238 231 155 128 120 86 67 73 99 2,267
2016 to 2017 0 8 351 328 264 247 222 170 150 130 90 67 64 91 2,182
2017 to 2018 0 10 323 329 271 242 232 147 160 128 83 76 60 71 2,132
2018 to 2019 1 6 287 310 289 238 201 166 148 94 75 87 52 101 2,055
Total 6 279 4,377 3,790 3,572 3,157 2,509 1,829 1,651 1,396 1,104 911 901 1,385 26,867
^Percent                              
2007 to 2008 0.0 2.1 11.7 14.4 15.0 11.8 8.7 6.2 5.7 5.4 4.3 4.1 3.9 6.7 100
2008 to 2009 0.0 1.2 14.4 13.6 15.4 12.7 7.9 5.8 5.9 5.0 4.1 3.6 3.8 6.6 100
2009 to 2010 0.0 1.3 16.2 15.0 14.6 12.3 8.7 5.6 5.3 5.0 3.7 3.6 3.0 5.6 100
2010 to 2011 0.0 1.3 15.8 12.6 13.3 11.9 9.2 7.1 5.9 6.1 4.3 3.3 3.3 5.9 100
2011 to 2012 0.0 0.9 16.4 12.8 13.0 13.6 9.7 6.6 5.7 5.2 3.7 3.1 3.7 5.4 100
2012 to 2013 0.0 1.5 17.4 14.3 11.5 11.3 8.5 6.9 6.8 4.9 4.9 3.6 3.7 4.9 100
2013 to 2014 0.0 1.2 19.2 13.9 12.4 11.0 9.3 6.8 5.5 4.2 4.8 3.0 3.5 5.0 101
2014 to 2015 0.0 0.9 18.8 13.6 12.6 11.5 9.1 7.4 5.9 4.9 4.1 2.8 3.7 4.7 102
2015 to 2016 0.0 0.8 20.0 13.6 12.7 10.5 10.2 6.8 5.6 5.3 3.8 3.0 3.2 4.4 103
2016 to 2017 0.0 0.4 16.1 15.0 12.1 11.3 10.2 7.8 6.9 6.0 4.1 3.1 2.9 4.2 104
2017 to 2018 0.0 0.5 15.2 15.4 12.7 11.4 10.9 6.9 7.5 6.0 3.9 3.6 2.8 3.3 105
2018 to 2019 0.0 0.3 14.0 15.1 14.1 11.6 9.8 8.1 7.2 4.6 3.6 4.2 2.5 4.9 106
Total 0.0 1.0 16.3 14.1 13.3 11.8 9.3 6.8 6.1 5.2 4.1 3.4 3.4 5.2 100

1Audit year between 1 April and 31 March

£ Note that women diagnosed aged 24.5 to 25 are included in the age group 25 to 29.

Table 3. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019 by audit year and age group

Audit Year <25£ 25 to 49 50 to 64 65+ Total
2016 to 2017 8 1,412 450 312 2,182
2017 to 2018 10 1,397 435 290 2,132
2018 to 2019 7 1,325 408 315 2,055
Total 25 4,134 1,293 917 6,369
Percent          
2016 to 2017 0.4 64.7 20.6 14.3 100
2017 to 2018 0.5 65.5 20.4 13.6 100
2018 to 2019 0.3 64.5 19.9 15.3 100
Total 0.4 64.9 20.3 14.4 100
£Note that women diagnosed aged 24.5 to 25 are included in the age group 25 to 29.          

Table 4. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by FIGO Stage

Cases
FIGO Stage n %
IA NOS 411 6.5
IA1 1,476 23.2
IA2 106 1.7
IB+ NOS* 584 9.2
IB NOS* 1,141 17.9
IB1 148 2.3
IB2 66 1.0
II NOS* 142 2.2
IIA 1,022 16.0
IIB 55 0.9
III NOS* 44 0.7
IIIA 301 4.7
IIIB 156 2.4
IV NOS* 181 2.8
IVA 189 3.0
IVB 74 1.2
None available 104 1.6
None recorded 169 2.7
Total 6,369 100
*NOS= not otherwise specified (or not further specified)    

Table 5. Number of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019 by age group and FIGO stage

Age IA IB II III IV IB+(NOS) None Recorded Total
<25£ 5 8 8 1 2 1 0 25
25 to 49 1,775 1,339 551 144 173 33 119 4,134
50 to 64 184 369 362 107 163 24 84 1,293
65+ 29 157 309 148 188 16 70 917
Total 1,993 1,873 1,230 400 526 74 273 6,369

£Note that women diagnosed aged 24.5 to 25 are included in the age group 25 to 29.

Table 5a. FIGO stage of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019: estimated percentage distribution, by age 

Age IA IB II+III IV Total
<25£ 21.3 33.9 36.7 8.1 100
25 to 49 44.6 33.6 17.4 4.4 100
50 to 64 16.4 31.0 38.9 13.8 100
65+ 4.0 19.6 53.9 22.6 100
All ages 32.9 31.0 27.1 8.9 100

£Note that women diagnosed aged 24.5 to 25 are included in the age group 25 to 29.

Table 6. Number of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by FIGO stage and year of diagnosis

Audit year* IA IB II III IV IB+(NOS) None Recorded Total
2007 to 2008 655 630 264 144 89 120 231 2,133
2008 to 2009 692 689 300 148 121 92 248 2,290
2009 to 2010 835 772 301 171 129 104 208 2,520
2010 to 2011 692 628 324 139 122 87 183 2,175
2011 to 2012 795 690 302 143 157 97 176 2,360
2012 to 2013 712 679 393 144 149 60 165 2,302
2013 to 2014 697 685 353 145 165 50 115 2,210
2014 to 2015 756 640 406 132 132 54 121 2,241
2015 to 2016 737 690 386 149 169 28 108 2,267
2016 to 2017 704 638 423 140 168 29 80 2,182
2017 to 2018 657 630 416 139 191 17 82 2,132
2018 to 2019 632 605 391 121 167 28 111 2,055
Total 8,564 7,976 4,259 1,715 1,759 766 1,828 26,867

*Audit year between 1 April and 31 March

Table 6a. FIGO stage of invasive cervical cancer cases: estimated percentage distribution, by year of diagnosis

Audit year IA IB II+III IV Total
2007 to 2008 35.7 35.4 23.2 5.6 100
2008 to 2009 34.7 35.2 23.5 6.7 100
2009 to 2010 36.5 35.1 22.2 6.3 100
2010 to 2011 35.6 33.1 24.6 6.8 100
2011 to 2012 37.1 33.1 22.1 7.8 100
2012 to 2013 34.4 31.9 26.1 7.6 100
2013 to 2014 34.2 33.1 24.5 8.2 100
2014 to 2015 34.1 32.0 26.9 7.0 100
2015 to 2016 34.4 32.3 25.2 8.0 100
2016 to 2017 33.8 30.9 27.1 8.2 100
2017 to 2018 32.1 30.8 27.5 9.7 100
2018 to 2019 32.9 31.5 26.7 8.9 100
Total 34.7 32.9 24.9 7.5 100

*Audit year between 1 April and 31 March

Table 7. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by histology

Audit year Squamous Adenocarcinoma Adeno-Squamous Undifferentiated Other None recorded Total
2007 to 2008 1,496 406 59 12 30 130 2,133
2008 to 2009 1,615 459 67 14 30 105 2,290
2009 to 2010 1,795 504 75 11 33 102 2,520
2010 to 2011 1,597 399 55 4 41 79 2,175
2011 to 2012 1,692 459 67 14 37 91 2,360
2012 to 2013 1,619 479 68 6 31 99 2,302
2013 to 2014 1,564 446 66 6 44 84 2,210
2014 to 2015 1,508 448 63 4 37 181 2,241
2015 to 2016 1,331 404 34 8 41 449 2,267
2016 to 2017 1,302 357 47 6 42 428 2,182
2017 to 2018 1,457 438 41 4 32 160 2,132
2018 to 2019 1,408 375 38 8 31 195 2,055
Total 18,384 5,174 680 97 429 2,103 26,867
Percent              
2007 to 2008 70.1 19.0 2.8 0.6 1.4 6.1 100
2008 to 2009 70.5 20.0 2.9 0.6 1.3 4.6 100
2009 to 2010 71.2 20.0 3.0 0.4 1.3 4.0 100
2010 to 2011 73.4 18.3 2.5 0.2 1.9 3.6 100
2011 to 2012 71.7 19.4 2.8 0.6 1.6 3.9 100
2012 to 2013 70.3 20.8 3.0 0.3 1.3 4.3 100
2013 to 2014 70.8 20.2 3.0 0.3 2.0 3.8 100
2014 to 2015 67.3 20.0 2.8 0.2 1.7 8.1 100
2015 to 2016 58.7 17.8 1.5 0.4 1.8 19.8 100
2016 to 2017 59.7 16.4 2.2 0.3 1.9 19.6 100
2017 to 2018 68.3 20.5 1.9 0.2 1.5 7.5 100
2018 to 2019 68.5 18.2 1.8 0.4 1.5 9.5 100
Total 68.4 19.3 2.5 0.4 1.6 7.8 100

*Audit year between 1 April and 31 March

Table 8. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by age at diagnosis and histology

Age Squamous Adenocarcinoma Adeno-Squamous Other (incl undiff) None recorded Total
<25 13 3 1 3 5 25
25 to 49 2,740 739 77 56 522 4,134
50 to 64 820 272 28 34 139 1,293
65+ 594 156 20 30 117 917
Total 4,167 1,170 126 123 783 6,369
Percent            
<25 52.0 12.0 4.0 12.0 20.0 100
25 to 49 66.3 17.9 1.9 1.4 12.6 100
50 to 64 63.4 21.0 2.2 2.6 10.8 100
65+ 64.8 17.0 2.2 3.3 12.8 100
Total 65.4 18.4 2.0 1.9 12.3 100

Table 9. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by FIGO Stage and histology

Stage Squamous Adenocarcinoma Adeno-Squamous Other (incl undiff) None recorded Total
IA 1,472 240 7 18 256 1,993
IB 1,012 547 59 27 228 1,873
II&III 1,124 230 40 32 204 1,630
IV 330 78 16 26 76 526
IB+(NOS) 45 22 1 4 2 74
None recorded 184 53 3 16 17 273
Total 4,167 1,170 126 123 783 6,369
Percent            
IA 35.3 20.5 5.6 14.6 32.7 31.3
IB 24.3 46.8 46.8 22.0 29.1 29.4
II&III 27.0 19.7 31.7 26.0 26.1 25.6
IV 7.9 6.7 12.7 21.1 9.7 8.3
IB+(NOS) 1.1 1.9 0.8 3.3 0.3 1.2
None recorded 4.4 4.5 2.4 13.0 2.2 4.3
Total 100 100 100 100 100 100
Treatment <25 25 to 49 50 to 64 65+ Total
None 1 72 25 62 160
Cone biopsy/ Loop excision 6 1,288 98 15 1,407
Trachalectomy 1 112 2 1 116
Simple hysterectomy 0 274 72 15 361
Radical hysterectomy 3 566 173 47 789
Radiotherapy ± hysterectomy 0 23 10 11 44
Chemotherapy ± hysterectomy 0 8 4 3 15
Chemotherapy + radiotherapy ± hysterectomy 0 66 25 12 103
Radiotherapy 0 46 56 159 261
Chemotherapy 0 101 58 40 199
Radiothearpy + Chemotherapy 8 642 424 284 1,358
Palliative care 0 19 30 62 111
Other 0 2 0 0 2
None recorded 6 915 316 206 1,443
Total 25 4,134 1,293 917 6,369

Table 10. Number of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by treatment and age group

Table 10a. Proportion of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by treatment and age group

Treatment <25 25 to 49 50 to 64 65+ Total
None 4.0 1.7 1.9 6.8 2.5
Cone biopsy/ Loop excision 24.0 31.2 7.6 1.6 22.1
Trachalectomy 4.0 2.7 0.2 0.1 1.8
Simple hysterectomy 0.0 6.6 5.6 1.6 5.7
Radical hysterectomy 12.0 13.7 13.4 5.1 12.4
Radiotherapy ± hysterectomy 0.0 0.6 0.8 1.2 0.7
Chemotherapy ± hysterectomy 0.0 0.2 0.3 0.3 0.2
Chemotherapy + radiotherapy ± hysterectomy 0.0 1.6 1.9 1.3 1.6
Radiotherapy 0.0 1.1 4.3 17.3 4.1
Chemotherapy 0.0 2.4 4.5 4.4 3.1
Radiothearpy + Chemotherapy 32.0 15.5 32.8 31.0 21.3
Palliative care 0.0 0.5 2.3 6.8 1.7
Other 0.0 0.0 0.0 0.0 0.0
None recorded 24.0 22.1 24.4 22.5 22.7
Total 100 100 100 100 100

Table 11. Number and proportion of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by age at diagnosis and treatment

Treatment <50 50 to 64 65 to 79 80+ Total
None(palliative) 92 55 58 66 271
Cone biopsy/ Loop excision 1,294 98 8 7 1,407
Trachalectomy 113 2 1 0 116
Hysterectomy only (simple or radical) 843 245 51 11 1,150
Radiotherapy ± hysterectomy 69 66 93 77 305
Chemotherapy ± hysterectomy 109 62 36 7 214
Chemo + radiotherapy ± hysterectomy 716 449 264 32 1,461
Not recorded (Other) 923 316 143 63 1,445
Total 4,159 1,293 654 263 6,369
Percent          
None(palliative) 2.2 4.3 8.9 25.1 4.3
Cone biopsy/ Loop excision 31.1 7.6 1.2 2.7 22.1
Trachalectomy 2.7 0.2 0.2 0.0 1.8
Hysterectomy only (simple or radical) 20.3 18.9 7.8 4.2 18.1
Radiotherapy ± hysterectomy 1.7 5.1 14.2 29.3 4.8
Chemotherapy ± hysterectomy 2.6 4.8 5.5 2.7 3.4
Chemo + radiotherapy ± hysterectomy 17.2 34.7 40.4 12.2 22.9
Not recorded (Other) 22.2 24.4 21.9 24.0 22.7
Total 100 100 100 100 100

Table 12. Number of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019, by FIGO Stage and treatment

Treatment IA IB II III IV IB+(NOS) None recorded Total
None(palliative) 38 39 30 34 106 0 24 271
Cone biopsy/ Loop excision 1,179 182 15 5 3 2 21 1,407
Trachalectomy 11 101 2 0 0 0 2 116
Hysterectomy only (simple or radical) 300 791 33 6 4 2 14 1,150
Radiotherapy ± hysterectomy 4 64 117 41 62 2 15 305
Chemotherapy ± hysterectomy 1 25 58 28 93 1 8 214
Chemo + radiotherapy ± hysterectomy 21 242 782 222 173 2 19 1,461
Not recorded (Other) 439 429 193 64 85 65 170 1,445
Total 1,993 1,873 1,230 400 526 74 273 6,369

Table 12a. FIGO stage of invasive cervical cancer cases: estimated percentage distribution in the audit between 1 April 2016 and 31 March 2019, by treatment

Treatment IA IB II+III IV Total
None(palliative) 15.0 15.7 26.3 43.1 100
Cone biopsy/ Loop excision 85.1 13.3 1.5 0.2 100
Trachalectomy 10.7 87.6 1.8 0.0 100
Hysterectomy only (simple or radical) 26.4 69.8 3.5 0.4 100
Radiotherapy ± hysterectomy 1.4 21.7 55.1 21.8 100
Chemotherapy ± hysterectomy 0.5 12.2 41.9 45.3 100
Chemo + radiotherapy ± hysterectomy 1.5 16.8 69.7 12.0 100
Not recorded (Other) 35.8 35.0 21.9 7.3 100
Total 32.9 31.0 27.1 8.9 100

Table 13. Cervical screening status of invasive cervical cancer cases and controls aged 25 to 64 in the audit between 1 April 2016 and 31 March 2019, up to 6 months prior to diagnosis (proportions)

Cervical screening status up to six months prior to diagnosis Population Controls Cases Stage IA Cases Stage IB+ Cases Stage not recorded
  n % n % n % n %
No cytology test (except within 6 months of diag) 1,519 14.4 755 38.5 1,212 37.1 51 25.1
Last test routine and                
Up to date 6,387 60.5 415 21.2 649 19.9 49 24.1
Lapsed 1,876 17.8 454 23.2 889 27.2 62 30.5
Last test early repeat                
Up to date 109 1.0 31 1.6 23 0.7 1 0.5
Lapsed 406 3.8 90 4.6 250 7.7 20 9.9
Last test suspend                
Up to date 52 0.5 15 0.8 15 0.5 3 1.5
Lapsed 203 1.9 199 10.2 227 7.0 17 8.4
Total 10,552 100 1,959 100 3,265 100 203 100

We have used the action code provided by the Exeter call  nd recall service to determine whether the last cytology test lead to a routine recall, early recall or suspend from the recall programme. After a routine recall interval, we consider the screening to be up to date when the diagnosis occurred within 3.5 years (or 5.5 years for older people) from the routine cytology test. After an action code of early repeat, we consider the screening to be up to date when the diagnosis occurred within 1.25 years (or 0.25 years if the test was inadequate) of the early repeat test. When the last test (6 months before diagnosis) resulted in a ‘suspend’ code recommending referral to colposcopy and was followed by at least one negative test, people were up to date if the diagnosis was made within 1.5 years of the test leading to the suspend code. Those that were suspended more than 6 months before diagnosis and are not followed by any negative tests are lapsed.

Table 14 Cervical screening status of invasive cervical cancer cases and controls up to 6 months prior to diagnosis (numbers and proportions) in the audit between 1 April 2016 and 31 March 2019, by age

Cervical screening status up to six months prior to diagnosis All Cases Controls
20-24 25 to 49 50 to 64 65 to 79 80+ 20 to 24 25 to 49 50 to 64 65 to 79 80+      
No cytology test (except within six months of diag) 25 1,686 332 194 86 47 1,420 99 88 148    
Last test routine and                        
Up to date 0 784 329 258 144 1 4,631 1,756 895 311    
Lapsed 0 990 415 144 16 0 1,334 542 247 42    
Last test early repeat and                        
Up to date 0 47 8 2 9 0 96 13 6 1    
Lapsed 0 250 110 37 8 0 328 78 33 11    
Last test suspend* 0 377 99 19 0 0 224 31 9 1    
Total 25 4,134 1,293 654 263 48 8,033 2,519 1,278 514    
Percent                        
No cytology test (except within six months of diag) 100 40.8 25.7 29.7 32.7 97.9 17.7 3.9 6.9 28.8    
Last test routine and                        
Up to date 0.0 19.0 25.4 39.4 54.8 2.1 57.6 69.7 70.0 60.5    
Lapsed 0.0 23.9 32.1 22.0 6.1 0.0 16.6 21.5 19.3 8.2    
Last test early repeat and                        
Up to date 0.0 1.1 0.6 0.3 3.4 0.0 1.2 0.5 0.5 0.2    
Lapsed 0.0 6.0 8.5 5.7 3.0 0.0 4.1 3.1 2.6 2.1    
Last test suspend* 0.0 9.1 7.7 2.9 0.0 0.0 2.8 1.2 0.7 0.2    
Total 100 100 100 100 100 100 100 100 100 100    
  • The categories “last test suspend (not followed by any negative)” and “last test suspend (followed by at least one negative)” found in table 14 are combined due to small numbers. Note that screening histories for women over age 65 are based on tests at ages 50-64.

Table 15. Number and percentage of population controls (GP plus district controls) screened in the 3 to 5-year interval preceding the date of diagnosis of their matched case, by age

Age Total Not screened in previous interval Screened once in previous interval Screened twice in previous interval Screened ≥3 times in previous interval
20 to 24   255 202 53 0 0    
25 to 29   1,666 682 916 55 13    
30 to 34   1,875 654 1,152 58 11    
35 to 39   1,595 550 991 44 10    
40 to 44   1,425 501 893 26 5    
45 to 49   1,265 414 824 25 2    
50 to 54   940 223 455 248 14    
55 to 59   894 275 588 21 10    
60 to 64   685 216 451 12 6    
65 to 69   482 155 318 6 3    
70 to 74   449 110 287 45 7    
75 to 79   347 92 166 68 21    
80+   514 191 220 94 9    
Total   12,392 4,265 7,314 702 111    
Percent National Coverage reported in 2018* Coverage (>=1 test in interval) % % % %    
20 to 24 2.2 20.8† 79.2 20.8 0.0 0.0    
25 to 29 64.2 59.1 40.9 55.0 3.3 0.8    
30 to 34 75.8 65.1 34.9 61.4 3.1 0.6    
35 to 39 77.9 65.5 34.5 62.1 2.8 0.6    
40 to 44 79.6 64.8 35.2 62.7 1.8 0.4    
45 to 49 80.1 67.3 32.7 65.1 2.0 0.2    
50 to 54 78.4 76.3 23.7 48.4 26.4 1.5    
55 to 59 72.6 69.2 30.8 65.8 2.3 1.1    
60 to 64 68.9 68.5 31.5 65.8 1.8 0.9    
65 to 69 - 67.8 32.2 66.0 1.2 0.6    
70 to 74 - 75.5 24.5 63.9 10.0 1.6    
75 to 79 - 73.5 26.5 47.8 19.6 6.1    
80+ - 62.8 37.2 42.8 18.3 1.8    
Total     34.4 59.0 5.7 0.9    

*Source: NHS Cervical Screening Programme in England in 2018-19. Note: we have used the 3.5 yearly coverage for women aged 20-49 and the 5.5 yearly coverage for women aged 50-64 using table 1a (see reference 2)

† Note: 77% of controls aged 20-24 are aged 24, only 3% are aged 20 or 21. Thus this age group is a reflection of the age at which their matched cases were diagnosed and not of the distribution of women aged 20-24 nationally. This explains the difference in coverage nationally and in the audit.

Table 15a. Number and proportion of population controls (GP plus district controls) screened in the 3 to 5-year interval preceding the date of diagnosis of their matched case, by age group

Age group Total Not screened in previous interval Screened once in previous interval Screened twice in previous interval Screened ≥3 times in previous interval
<24.5 48 46 2 0 0
25 to 34 3,748 1,492 2,119 113 24
35 to 49 4,285 1,465 2,708 95 17
50 to 64 2,519 714 1,494 281 30
65 to 74 931 265 605 51 10
75+ 861 283 386 162 30
Total 12,392 4,265 7,314 702 111
Percent Coverage (>=1 test in interval)        
<24.5 4.2 95.8 4.2 0.0 0.0
25 to 34 60.2 39.8 56.5 3.0 0.6
35 to 49 65.8 34.2 63.2 2.2 0.4
50 to 64 71.7 28.3 59.3 11.2 1.2
65 to 74 71.5 28.5 65.0 5.5 1.1
75+ 67.1 32.9 44.8 18.8 3.5
Total   34.4 59.0 5.7 0.9

Table 16. Time to previous cytology among screened controls 1,2

Time to previous screen
Age <2.75 yrs 2.75-3.5 yrs 3.5-4.75 yrs 4.75-5.5 yrs 5.5-9.5 yrs No previous cytology within 9.5 years Total
25 to 29 14 94 30 4 3 157 302
30 to 34 17 158 47 13 42 64 341
35 to 39 10 137 31 9 35 39 261
40 to 44 9 101 37 4 26 19 196
45 to 49 2 91 27 5 25 10 160
50 to 54 0 38 8 5 14 6 71
55 to 59 1 0 1 34 18 7 61
60 to 64 0 0 1 41 6 1 49
Total 53 619 182 115 169 303 1,441
Percent              
25 to 29 4.6 31.1 9.9 1.3 1.0 52.0 100
30 to 34 5.0 46.3 13.8 3.8 12.3 18.8 100
35 to 39 3.8 52.5 11.9 3.4 13.4 14.9 100
40 to 44 4.6 51.5 18.9 2.0 13.3 9.7 100
45 to 49 1.3 56.9 16.9 3.1 15.6 6.3 100
50 to 54 0.0 53.5 11.3 7.0 19.7 8.5 100
55 to 59 1.6 0.0 1.6 55.7 29.5 11.5 100
60 to 64 0.0 0.0 2.0 83.7 12.2 2.0 100
Total 3.7 43.0 12.6 8.0 11.7 21.0 100

1 When a case is identified as potentially screen-detected (one in which cytology results are consistent with screen detection) a screen control is then selected (one with a cytology test taken close in calendar time to the test from which the case was screen detected).

2 Screened controls from cases in the audit between 1 April 2016 and 31 March 2019.

Table 16a. Time to previous cytology test among potentially screen-detected1,2 cases of cervical cancer and their screened controls

Time to previous screen
Age <3.5 yrs 3.5-4.75 yrs 4.75-5.5 yrs 5.5-9.5 yrs No previous cytology within 9.5 yrs Total <5.5 yrs                  
  Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls    
28 to 34 222 256 84 75 22 16 51 43 138 113 517 503 328 347    
35 to 49 183 350 69 95 16 18 112 86 247 68 627 617 268 463    
50 to 64 20 39 5 10 53 80 36 38 68 14 182 181 78 129    
Total 425 645 158 180 91 114 199 167 453 195 1,326 1,301 674 939    
Percent                                
  Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls    
28 to 34 42.9 50.9 16.2 14.9 4.3 3.2 9.9 8.5 26.7 22.5 100 100 63.4 69.0    
35 to 49 29.2 56.7 11.0 15.4 2.6 2.9 17.9 13.9 39.4 11.0 100 100 42.7 75.0    
50 to 64 11.0 21.5 2.7 5.5 29.1 44.2 19.8 21.0 37.4 7.7 100 100 42.9 71.3    
Total 32.1 49.6 11.9 13.8 6.9 8.8 15.0 12.8 34.2 15.0 100 100 50.8 72.2    

1 A potentially screen-detected case is one in which cytology results are consistent with screen detection; there is no national record of whether the cytology was in response to screening or to symptoms

2 Screen-detected cases in the audit between 1 April 2016 and 31 March 2019.

Table 17. Maximum interval* between cytology tests (over the previous 8 years) among cases with FIGO stage 1B+ diagnosed in the audit between 1 April 2016 and 31 March 2019 and their population controls

Age <3.5 yrs 3.5-4.75 yrs 4.75-5.5 yrs 5.5-7yrs >7 yrs or no cytology Total
  Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
28 to 34 73 304 122 369 75 184 42 151 365 306 677 1,314
35 to 49 167 1,101 160 580 68 218 103 266 907 563 1,405 2,728
50 to 64 61 344 84 458 141 523 65 218 674 449 1,025 1,992
Total 301 1,749 366 1,407 284 925 210 635 1,946 1,318 3,107 6,034
Percent                        
28 to 34 10.8 23.1 18.0 28.1 11.1 14.0 6.2 11.5 53.9 23.3 100 100
35 to 49 11.9 40.4 11.4 21.3 4.8 8.0 7.3 9.8 64.6 20.6 100 100
50 to 64 6.0 17.3 8.2 23.0 13.8 26.3 6.3 10.9 65.8 22.5 100 100
Total 9.7 29.0 11.8 23.3 9.1 15.3 6.8 10.5 62.6 21.8 100 100

 * This analysis shows the longest period between tests in the 8 years preceding the date of diagnosis of the case. People under age 28 are not included in this analysis because (even allowing for screening from age 20) they would not have been eligible for screening for the whole of the previous 8 years.

Table 18. Number and percentage of invasive cervical cancer cases in the audit between 1 April 2016 and 31 March 2019 with colposcopic appointment recorded, by age group

Age group Number of cases Cases with a recorded colposcopy Cases with a colposcopy review record* Cases with an action code “suspend” Cases with a “suspend” code >4 months before diagnosis Cases with “Suspend” >4 months before diagnosis + colposcopy Cases with “Suspend” >4 months before diagnosis + colposcopy (excluding colposcopy  within 2 months of diagnosis)
    n % n % n % n % n % n %
<25 25 11 44.0 0 - 4 16.0 0 0.0 0 - 0 -
25-34 1,928 1,412 73.2 125 79.6 1,544 80.1 208 10.8 157 75.5 115 55.3
35-49 2,206 1,421 64.4 131 43.4 1,536 69.6 432 19.6 302 69.9 156 36.1
50-64 1,293 556 43.0 50 33.6 661 51.1 280 21.7 149 53.2 76 27.1
65-74 478 97 20.3 9 42.9 103 21.5 78 16.3 21 26.9 9 11.5
75+ 439 82 18.7 8 88.9 45 10.3 40 9.1 9 22.5 4 10.0
Total 6,369 3,579 56.2 323 50.6 3,893 61.1 1038 16.3 638 61.5 360 34.7

*Percent with a colposcopy review is out of those with a suspend code >4 months before diagnosis + colposcopy.

Table 19. Original cytology result by review result from cases diagnosed in the audit between 1 April 2006 and 31 March 2019 *

Review Result

Original result Negative Inadequate Borderline Low-grade (mild) ?Glandular (non-cervical) High-grade (Moderate) High-grade (severe) ?Invasive ?Glandular Total
  N % N % N % N % N % N % N % N % N % N %
Negative 10015 52.3 863 4.5 3276 17.1 371 1.9 13 0.1 595 3.1 2558 13.4 133 0.7 1316 6.9 19140 100
Inadequate 150 9.3 881 54.4 237 14.6 23 1.4 1 0.1 35 2.2 184 11.4 34 2.1 75 4.6 1620 100
Borderline 86 2.7 31 1.0 1288 40.5 239 7.5 5 0.2 210 6.6 853 26.8 64 2.0 408 12.8 3184 100
Low-grade (mild) 16 1.6 2 0.2 88 8.8 451 44.9 0 0.0 181 18.0 211 21.0 31 3.1 25 2.5 1005 100
?Glandular (non-cervical) 0 0.0 0 0.0 0 0.0 0 0.0 7 50.0 0 0.0 0 0.0 5 35.7 2 14.3 14 100
High-grade (moderate) 5 0.6 0 0.0 8 1.0 22 2.7 1 0.1 293 36.3 417 51.7 38 4.7 23 2.9 807 100
High-grade (severe) 13 0.3 2 0.0 12 0.3 5 0.1 0 0.0 31 0.7 3444 82.1 458 10.9 229 5.5 4194 100
?Invasive 4 0.3 0 0.0 2 0.1 0 0.0 0 0.0 0 0.0 120 8.1 1338 90.2 20 1.3 1484 100
?Glandular 4 0.3 2 0.2 5 0.4 0 0.0 0 0.0 1 0.1 63 5.1 27 2.2 1130 91.7 1232 100
Total 10293 31.5 1781 5.4 4916 15.0 1111 3.4 27 0.1 1346 4.1 7850 24.0 2128 6.5 3228 9.9 32680 100
  • This is an updated version of Table 1 in Castanon et al , Cytopathology, 2012.  

Table 20. Review result from cases diagnosed in the audit between 1 April 2007 and 31 March 2019 with a negative cytology result within 2 years of diagnosis by audit year of diagnosis

Review Result

Audit report period Negative Inadequate Borderline Low-grade (mild) ?Glandular (non-cervical) High-grade (Moderate) High-grade (severe) ?Invasive ?Glandular Total
  N % N % N % N % N % N % N % N % N % N %  
  April 2007 to March 2013* 464 41.4 25 2.2 217 19.3 25 2.2 2 0.2 35 3.1 188 16.8 31 2.8 135 12.0 1,122 100
  April 2013 to March 2016 185 38.1 6 1.2 126 25.9 5 1.0 6 1.2 12 2.5 88 18.1 10 2.1 48 9.9 486 100
  April 2016 to March 2019 141 34.1 6 1.4 73 17.6 8 1.9 2 0.5 12 2.9 89 21.5 21 5.1 62 15.0 414 100
  Total 790 39.1 37 1.8 416 20.6 38 1.9 10 0.5 59 2.9 365 18.1 62 3.1 245 12.1 2,022 100

*To note that the criteria for determining cases requiring review changed after March 2013

Table 21. Review result from cases diagnosed in the audit between 1 April 2007 and 31 March 2019 with a negative cytology result taken between 2 and 4 years prior to diagnosis by audit year of diagnosis

Review Result

Audit report period Negative Inadequate Borderline Low-grade (mild) ?Glandular (non-cervical) High-grade (Moderate) High-grade (severe) ?Invasive ?Glandular Total
N % N % N % N % N % N % N % N % N % N %  
April 2007 to March 2013 1285 45.5 90 3.2 597 21.1 64 2.3 0 0.0 94 3.3 464 16.4 29 1.0 200 7.1 2,823 100
April 2013 to March 2016 551 43.1 11 0.9 230 18.0 15 1.2 0 0.0 44 3.4 267 20.9 12 0.9 148 11.6 1,278 100
April 2016 to March 2019 589 42.3 6 0.4 206 14.8 20 1.4 3 0.2 75 5.4 311 22.3 6 0.4 176 12.6 1,392 100
Total 2425 44.1 107 1.9 1033 18.8 99 1.8 3 0.1 213 3.9 1042 19.0 47 0.9 524 9.5 5,493 100

Table 22. Audit of Invasive Cervial Cancer: number and percentage of deprivation quintiles of cases of invasive cervical cancer by age group at diagnosis

Deprivation quintiles <25 25 to 49 50 to 64 65+ Total
0 to 1 9 1,017 311 176 1,513
2 to 3 7 788 229 171 1,195
4 to 5 1 687 215 159 1,062
6 to 7 4 594 198 148 944
8 to 10 2 563 204 184 953
Total 23 3,649 1,157 838 5,667
Percent          
0 to 1 39% 28% 27% 21% 27%
2 to 3 30% 22% 20% 20% 21%
4 to 5 4% 19% 19% 19% 19%
6 to 7 17% 16% 17% 18% 17%
8 to 10 9% 15% 18% 22% 17%
Total 100% 100% 100% 100% 100%

Table 23. Audit of Invasive Cervial Cancer: number and percentage of deprivation quintiles of cases of invasive cervical cancer by FIGO stage at diagnosis

Deprivation quintiles 1A 1B 2 Total
0 to 1 499 451 563 1513
2 to 3 374 372 449 1195
4 to 5 339 343 380 1062
6 to 7 321 305 318 944
8 to 10 315 287 352 953
Total 1,847 1,758 2,063 5,667
         
0 to 1 27% 26% 27% 27%
2 to 3 20% 21% 22% 21%
4 to 5 18% 20% 18% 19%
6 to 7 17% 17% 15% 17%
8 to 10 17% 16% 17% 17%
Total 100% 100% 100% 100%
Back to top